跳轉至內容
Merck
全部照片(1)

重要文件

A-095

Supelco

Atomoxetine hydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C17H22ClNO
CAS號碼:
分子量::
291.82
EC號碼:
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

certified reference material

形狀

liquid

特點

SNAP-N-SPIKE®, SNAP-N-SHOOT®

包裝

ampule of 1 mL

製造商/商標名

Cerilliant®

濃度

1.0 mg/mL in methanol (as free base)

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

應用

forensics and toxicology

格式

single component solution

儲存溫度

−20°C

SMILES 字串

Cl.CNCC[C@@H](Oc1ccccc1C)c2ccccc2

InChI

1S/C17H21NO.ClH/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15;/h3-11,17-18H,12-13H2,1-2H3;1H/t17-;/m1./s1

InChI 密鑰

LUCXVPAZUDVVBT-UNTBIKODSA-N

基因資訊

human ... SLC6A2(6530)

一般說明

Atomoxetine is an attention-deficit hyperactivity disorder (ADHD) drug marketed in the US under the trade name Strattera®. This Certified Spiking Solution® is suitable for use in numerous testing applications such as clinical toxicology, forensic analysis, pharmaceutical research, urine drug testing, or calibrator preparation.

應用


  • Metabolic profiling of norepinephrine reuptake inhibitor atomoxetine.: This study investigates the metabolic pathways and profiles of atomoxetine, highlighting its pharmacokinetic properties. The research underscores the significance of Atomoxetine HCl solution in understanding the drug′s metabolism and its implications for ADHD treatment (MacKenzie et al., 2020).


  • Using Cell Cultures for the Investigation of Treatments for Attention Deficit Hyperactivity Disorder.: This systematic review explores the use of cell cultures in studying ADHD treatments, including atomoxetine. It provides insights into the cellular mechanisms and efficacy of Atomoxetine HCl, demonstrating its role in advancing ADHD pharmacological research (Chierrito et al., 2019).



法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Strattera is a registered trademark of Eli Lilly and Co.

訊號詞

Danger

危險分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

標靶器官

Eyes

儲存類別代碼

3 - Flammable liquids

水污染物質分類(WGK)

WGK 1

閃點(°F)

49.5 °F - closed cup

閃點(°C)

9.7 °C - closed cup


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Hedi Schelleman et al.
PloS one, 8(1), e52991-e52991 (2013-02-06)
To compare the incidence rates of serious cardiovascular events in adult initiators of amphetamines or atomoxetine to rates in non-users. This was a retrospective cohort study of new amphetamines (n=38,586) or atomoxetine (n=20,995) users. Each medication user was matched to
Chi-Yung Shang et al.
Journal of child and adolescent psychopharmacology, 22(5), 353-363 (2012-10-23)
Atomoxetine is efficacious in reducing symptoms of attention- deficit/hyperactivity disorder (ADHD), but its effect on visual memory and attention needs more investigation. This study aimed to assess the effect of atomoxetine on visual memory, attention, and school function in boys
Adriana Alexandre dos Santos Tavares et al.
Synapse (New York, N.Y.), 67(1), 30-41 (2012-10-09)
This study aims to investigate the pharmacokinetics of a recently developed radiotracer for imaging of the norepinephrine transporter (NET) in baboon brain, (123)I-INER, using single photon emission computed tomography (SPECT). In addition, it also aims to determine NET occupancy by
Emilia Marchei et al.
Drug testing and analysis, 5(3), 191-195 (2012-09-20)
Atomoxetine (ATX) is a selective norepinephrine reuptake inhibitor approved since 2002 for the treatment of attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults as an alternative treatment to methylphenidate. Within the framework of a project evaluating the use
Michael Turner et al.
Behavioural brain research, 243, 28-37 (2012-12-26)
Atomoxetine (ATX) is a commonly used non-stimulant treatment for Attention deficit hyperactivity disorder (ADHD). It primarily acts to increase noradrenalin levels; however, at higher doses it can increase dopamine levels. To date there has been no investigations into the effects

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務